Literature DB >> 12559388

Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Christine Konradi1, Stephan Heckers.   

Abstract

The glutamate system is involved in many aspects of neuronal synaptic strength and function during development and throughout life. Synapse formation in early brain development, synapse maintenance, and synaptic plasticity are all influenced by the glutamate system. The number of neurons and the number of their connections are determined by the activity of the glutamate system and its receptors. Malfunctions of the glutamate system affect neuroplasticity and can cause neuronal toxicity. In schizophrenia, many glutamate-regulated processes seem to be perturbed. Abnormal neuronal development, abnormal synaptic plasticity, and neurodegeneration have been proposed to be causal or contributing factors in schizophrenia. Interestingly, it seems that the glutamate system is dysregulated and that N-methyl-D-aspartate receptors operate at reduced activity. Here we discuss how the molecular aspects of glutamate malfunction can explain some of the neuropathology observed in schizophrenia, and how the available treatment intervenes through the glutamate system. Copyright 2002 Elsevier Science Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12559388      PMCID: PMC4203361          DOI: 10.1016/s0163-7258(02)00328-5

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  367 in total

1.  Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD.

Authors:  E C Beattie; R C Carroll; X Yu; W Morishita; H Yasuda; M von Zastrow; R C Malenka
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

2.  Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients.

Authors:  M I Aparicio-Legarza; B Davis; P H Hutson; G P Reynolds
Journal:  Neurosci Lett       Date:  1998-01-30       Impact factor: 3.046

Review 3.  Glutamate receptors in the mammalian central nervous system.

Authors:  S Ozawa; H Kamiya; K Tsuzuki
Journal:  Prog Neurobiol       Date:  1998-04       Impact factor: 11.685

4.  D-serine added to clozapine for the treatment of schizophrenia.

Authors:  G E Tsai; P Yang; L C Chung; I C Tsai; C W Tsai; J T Coyle
Journal:  Am J Psychiatry       Date:  1999-11       Impact factor: 18.112

5.  Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics.

Authors:  A E Evins; E T Amico; V Shih; D C Goff
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  Characterization of haloperidol and trifluperidol as subtype-selective N-methyl-D-aspartate (NMDA) receptor antagonists using [3H]TCP and [3H]ifenprodil binding in rat brain membranes.

Authors:  L L Coughenour; J J Cordon
Journal:  J Pharmacol Exp Ther       Date:  1997-02       Impact factor: 4.030

7.  Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort.

Authors:  P B Jones; P Rantakallio; A L Hartikainen; M Isohanni; P Sipila
Journal:  Am J Psychiatry       Date:  1998-03       Impact factor: 18.112

8.  Spontaneous dyskinesia in first episode schizophrenia.

Authors:  B K Puri; T R Barnes; M J Chapman; S B Hutton; E M Joyce
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-01       Impact factor: 10.154

9.  Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs.

Authors:  L W Fitzgerald; A Y Deutch; G Gasic; S F Heinemann; E J Nestler
Journal:  J Neurosci       Date:  1995-03       Impact factor: 6.167

Review 10.  Schizophrenia: a disconnection syndrome?

Authors:  K J Friston; C D Frith
Journal:  Clin Neurosci       Date:  1995
View more
  91 in total

Review 1.  Gene-environment interplay in schizopsychotic disorders.

Authors:  Tomas Palomo; Trevor Archer; Richard M Kostrzewa; Rrichard J Beninger
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

2.  Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.

Authors:  Nurith Amitai; Athina Markou
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

Review 3.  Targeting glutamate synapses in schizophrenia.

Authors:  Julie R Field; Adam G Walker; P Jeffrey Conn
Journal:  Trends Mol Med       Date:  2011-09-28       Impact factor: 11.951

Review 4.  Apolipoprotein D.

Authors:  Eric Rassart; Frederik Desmarais; Ouafa Najyb; Karl-F Bergeron; Catherine Mounier
Journal:  Gene       Date:  2020-06-15       Impact factor: 3.688

Review 5.  Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.

Authors:  Jiri Horacek; Vera Bubenikova-Valesova; Milan Kopecek; Tomas Palenicek; Colleen Dockery; Pavel Mohr; Cyril Höschl
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

Review 7.  [Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts].

Authors:  P Falkai; W Maier
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 8.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

9.  The role of Akt/FoxO3a in the protective effect of venlafaxine against corticosterone-induced cell death in PC12 cells.

Authors:  Haitao Wang; Xuanhe Zhou; Jianchu Huang; Nan Mu; Zeli Guo; Qiang Wen; Rikang Wang; Shaorui Chen; Zhong-Ping Feng; Wenhua Zheng
Journal:  Psychopharmacology (Berl)       Date:  2013-03-15       Impact factor: 4.530

10.  NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity.

Authors:  Bo Li; Nino Devidze; Denis Barengolts; Naseem Prostak; Eleana Sphicas; Alfonso J Apicella; Roberto Malinow; Effat S Emamian
Journal:  J Neurosci       Date:  2009-09-23       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.